Elsevier’s SciVal Funding Expands Globally
Amsterdam – 24 June, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the expansion of SciVal Funding to regions outside of the United States, enabling institutions to identify international funding opportunities.
Through the international expansion of SciVal Funding, researchers, research administrators and research development professionals in Canada, the United Kingdom and the European Union will now have access to relevant funding opportunities and awarded grant data under a single integrated solution. SciVal Funding will be expanded to Australia in August and to Singapore, South Africa, India, New Zealand and Ireland by the end of 2011.
“Increasing funding application success rates in today’s increasingly collaborative and international research community requires a global perspective and access to appropriate resources,” said Niels Weertman, Vice-President SciVal, at Elsevier. “The expanded coverage of funding opportunities and awarded grants information of SciVal Funding highlights Elsevier’s ongoing commitment to empower institutions worldwide to implement performance, planning and funding strategies that are global in scope and collaborative in nature.”
Recognizing the challenges of increased competition for funding, Elsevier developed SciVal Funding to optimize the pre-award stage of the research cycle. The tool leads researchers, research administrators and research development professionals to grants with the greatest potential for success by integrating current funding opportunities with publication information and historical award data. Updated daily, funding opportunities can be explored by subject area, award type, deadline or amount. Also, SciVal Funding provides customized recommendations and alerts by matching funding opportunity data to pre-populated researcher profiles that are continuously updated. Research administrators may also use award information for performance measurement, evaluation and strategic planning purposes. Access to a comprehensive pool of funding opportunities as well as the ability to uncover new sources of financial support is especially critical in these uncertain economic times.
The inclusion of funding opportunities, award information and pre-populated researcher profiles from these newly added countries, as well as the addition of nearly 700 funding bodies to the more than 3,000 U.S.-based sources currently available in the platform, will allow institutions to discover international funding opportunities, resulting in more effective collaboration.
For more information on SciVal Funding and to request a trial, please visit www.info.scival.com.
About the Elsevier SciVal® Suite
Elsevier’s SciVal suite of services supports academic and government leadership in evaluating, establishing and executing research strategies that optimize the performance of existing assets and maximize investments to enhance near and long-term productivity. SciVal tools leverage Scopus® data, Elsevier’s trusted source of bibliometric data, to offer innovative yet authoritative solutions. Current suite offerings include: SciVal Spotlight™, a strategic tool that generates unique institutional and country maps of existing and emerging strengths based on an interdisciplinary perspective of current performance; SciVal Funding™, an online solution that provides targeted recommendations on grants to pursue based on pre-populated research profiles and historical awards; SciVal Experts, a semantic technology-based application that enables researchers to identify and locate sources of expertise at an individual or departmental level within and across institutions.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact